Selegiline in Treatment of Cocaine Dependence - 2

This study has been completed.

First Received: September 20, 1999 Last Updated: August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000188

Purpose

The purpose of this study is to assess selegiline as a pharmacotherapy for cocaine dependence.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Selegiline	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Selegiline in Treatment of Cocaine Dependence

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Selegiline Selegiline hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Retention
Cocaine use
Cocaine craving

Estimated Enrollment:	0
Study Start Date:	September 1994

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000188

Locations

United States, Pennsylvania
PDVAMC Treatment Research Center
Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

James Cornish, M.D.

University of Pennsylvania

More Information

No publications provided

Study ID Numbers:	NIDA-00144-2, K20-00144-2
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000188 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Antiparkinson Agents
Disorders of Environmental Origin
Enzyme Inhibitors
Neuroprotective Agents

Protective Agents
Pharmacologic Actions
Selegiline
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Monoamine Oxidase Inhibitors
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 27, 2009